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Getting admitted to a civilian or battlefield hospital these days 
often poses considerable risks and dangers. The ever-growing 
number of  emerging diseases worldwide makes treatment of  
patients difficult and sometimes impossible. Many antibiotics are 
no longer effective against the simplest infections, which result 
in further hospitalizations with increased costs to the patients 
and governments worldwide. Microorganisms of  prime concern 
include methicillin-resistant Staphylococcus aureus, Clostridium difficile, 
multidrug and extensive drug-resistant Mycobacterium tuberculosis, 
Neisseria gonorrhoeae, and carbapenem- resistant Enterobacteriaceae, as 
well as bacteria that produce extensive spectram beta-lactamases, 
such as E. coli. An unusual decline in the discovery of  new and 
effective antibiotics, these days, is only making matters worse.
Despite government interventions, using diverse plans and some 
funding, the germs appear to be winning [1]. It is sad, to say, that 
governments, worldwide, are often concealing many dangerous 
outbreaks in numerous hospitals, including military service 
facilities. Deaths due to infections that could not be treated 
properly are often listed as due to respiratory or heart failure on 
the death-certificates. It is often stated that within three to four 
decades, these “superbugs” will kill more people, worldwide, than 
all deaths due to cancer and heart disease combined [1]. The 
World Health Organization has indicated that there has been a 
seven-fold increase in drug-resistant infections over the past eight 
years just among hospitalized children in the USA [1]. How can 
we reverse these deadly outcomes?
HDFx: Discovery of  a New Host-defense 
Immunomodulator
For the past 30 years, our laboratories have been working on a new 
approach to develop host-defense factors that stimulate various 
arms of  the innate and adaptive immune systems. To this end , 
we have discovered HDFx, a heretofore unknown host-defense 
factor in all mammals so far investigated (i.e., mice, rats, guinea-
pigs, rabbits, dogs, and sub-human primates) [2-5]. We, thus, 
assume it is present in human subjects as well. About 135 years 
ago, Elie Metchnikoff, the father of  immunology, hypothesized 
that the body, under stressful circumstances, would manufacture/
release molecules that could stimulate different arms of  the 
innate immune system and serve to protect the host against 
major insults and diseases [6]. Metchnikoff ’s early studies pointed 
to the importance of  macrophages and phagocytic leukocytes 
to natural (innate) resistance against pathogenic bacteria and 
viruses. During these past 30-40 years, a considerable number 
of  studies on animals and humans, have demonstrated a strong 
relationship between the functional (physiological) state of  the 
microcirculation, macrophages-leukocytes, natural killer (NK) 
cells, the reticuloendothelial system, and “pit” cells in the liver 
to host-defense and resistance to pathogens, trauma, circulatory 
shock, and sepsis [7-14].
Numerous experiments from our laboratories have clearly shown 
that HDFx is protective (to varying degrees) against a variety 
of  systemic bodily insults ranging from hemorrhage, trauma, 
combined injuries, endotoxins, a variety of  lethal bacteria (e.g., 
E. coli, S. enteriditis, C. welchii, among others), fungi (e.g., Aspergillis 
fumagatus), centripetal forces, and septic shock [2-5, 15-19]. An 
important attribute of  HDFx is its unique ability to protect against 
"cytokine storms" in animals that are septic [19]; 'cytokine storms' 
are clearly known to be a major cause of  lethality in hospitalized 
patients infected with numerous microorganisms (i.e., bacteria and 
fungi) who become resistant to antibiotic treatment [14]. It should 
be noted, here, that multiple virus infections, such as dengue, 
hanta viruses, diverse hemorrhagic fever viruses, and influenza 
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viruses can also trigger massive cell destruction, resulting in 
extensive "cytokine storms" which play pivotal roles in promoting 
lethality of  patients in and out of  hospitals, and on the battlefields 
[14]. To our knowledge, no other host-defense factor can stem the 
dissemination in the body of  cytokines in sepsis, as can HDFx, 
at least experimentally in animals. Septic shock caused by severe 
bacterial/fungal infections accounts for about 10% of  all human 
deaths in the U.S.A. each year, and is major cause of  battlefield 
deaths and farm animal deaths each year.
HDFx and “Super-Superbugs”
Gran–negative “superbugs” seem to be the major culprits in 
many hospitalized patients and wounded military personnel on 
battlefields. Gram-negative bacteria are more difficult to kill than 
gram-positive bacteria because they are protected by “double 
membranes”. So, in order to kill the gram-negative bacteria, most 
of  the therapeutic approaches have been to design antibiotics 
to penetrate these membrane barriers. In our opinion, another 
likely approach would be to engulf  the bacteria and digest them 
within “supercharged” macrophages, Kupffer cells, phagocytic 
leukocytes, “pit cells” and NK cells. HDFx appears, at least 
experimentally, to induce a “supercharged effect” in these various 
types of  phagocytic cells in animals we have investigated to date. 
But for this kind of  effect to take place, in a most expeditious 
fashion, we believe the microcirculation in the various regional 
vascular beds (i.e., liver, spleen, and lungs) must perforce 
produce optimal (physiologic) blood flows and distribution of  
capillary, nutritive flows. Fortunately, HDFx also posseses unique 
vasoactive properties which act to do exactly the latter in the 
microcirculation [2-5]. To our knowledge, no other known host-
defense factor, other than HDFx, can accomplish this task under 
septic conditions.
Conclusions
The discovery of  HDFx may provide a unique way to ameliorate and 
prevent hospital-borne infections and be pivotal in the prevention 
of  deaths, amputations, and disfigurement of  wounded soldiers 
on the battlefield. We believe the approaches outlined, herein, and 
elsewhere [2-5, 15-18] regarding our discovery, or derivatives of  
HDFx, could be an ideal drug to pretreat all hospitalized patients 
and, especially, those scheduled for major surgeries.
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